Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma

Proteomic Analysis for Finding Serum Pathogenic Factors and Potential Biomarkers in Multiple Myeloma

Blog Article

Background: Multiple myeloma (MM) is a malignant tumor, which takes the second place in malignant blood disease.The clinical symptoms are complicated that make more difficult to diagnose and therapy.Lots of researches focus on the proteins about MM in order to solve those problems.

We used proteomic methods to find potential biomarkers in MM patients.Methods: We applied the peptide ligand library beads (PLLBs) Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole to deplete high abundance proteins in serum for finding potential pathogenic factors and biomarkers of MM.Using 1D-Gel-liquid chromatography-tandem mass spectrometry (LC-MS/MS), we identified 789 and 849 unique serum proteins in MM patients and Altered expression of cyclin A 1 in muscle of patients with facioscapulohumeral muscle dystrophy (FSHD-1). in healthy controls, respectively.

Results: Twenty-two proteins were found differentially expressed between the two groups including serum amyloid A protein, vitamin D-binding protein isoform-1 precursor, plasma kallikrein, and apolipoprotein A-I.Changes of integrin alpha-11 and isoform-1 of multimerin-1 were validated with Western blotting.The linkage of the differentially expressed proteins and the pathogenesis pathways of MM were discussed.

Conclusions: PLLB combined with 1D-gel-LC-MS/MS analysis is an efficient method to identify differentially expressed proteins in serum from patients with MM.